Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The MPN Channel

Explore the latest updates, including expert interviews, features, podcasts and e-learning

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Latest Videos The MPN Sessions Subtypes Conferences Features Podcasts Expert Editorial Board

Welcome to The Myeloproliferative Neoplasms (MPN) Channel

VJHemOnc brings you the newest developments in MPNs, including highly anticipated clinical research data, as well as cutting-edge diagnostic and treatment approaches presented at major international congresses. Also explore the latest clonal evolution discoveries, emerging therapies, and novel drug combinations, all in the form of exclusive video interviews, podcasts and roundtable discussions.

Subtypes

Essential Thrombocythemia
Myelofibrosis
Polycythemia Vera
Systemic Mastocytosis
Chronic Myelomonocytic Leukemia
3:32
The management of patients with ET or PV during pregnancy
Mary Frances McMullin • 7 Dec 2025
2:25
12-month primary endpoint analysis from the Phase III ROP-ET study of ropeginterferon alfa-2b in ET
Jean-Jacques Kiladjian • 8 Dec 2025
2:06
Safety & efficacy of INCA033989, a first-in-class mutant CALR-specific mAb, in patients with ET & MF
Claire Harrison • 8 Dec 2025
2:47
The role of HMGA1 in driving MPN progression
Linda Resar • 11 Sep 2025
View All Videos
1:40
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
Ruben Mesa • 6 Dec 2025
1:26
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Ruben Mesa • 6 Dec 2025
1:54
Therapeutic options available in the UK for patients with myelofibrosis
Mary Frances McMullin • 7 Dec 2025
2:37
Preliminary analysis of the FEDORA trial: fedratinib plus ropeginterferon alfa-2b in myelofibrosis
Mary Frances McMullin • 7 Dec 2025
View All Videos
3:32
The management of patients with ET or PV during pregnancy
Mary Frances McMullin • 7 Dec 2025
2:04
Patient-reported outcomes in the Phase III VERIFY trial of rusfertide for polycythemia vera
Aniket Bankar • 8 Dec 2025
1:52
Using artificial intelligence to accelerate patient eligibility screening in clinical trials
Aaron Gerds • 5 Dec 2025
2:03
Hematocrit control among patients with high- or low-risk PV receiving SoC treatment in the US
Aaron Gerds • 5 Dec 2025
View All Videos
3:57
The current and emerging therapies for systemic mastocytosis
Prithviraj Bose • 22 Aug 2025
12:27
Challenging and uncommon scenarios in MPNs
Andreas Reiteret al. • 27 Jun 2025
1:15
Diagnosing and treating systemic mastocytosis with an associated hematologic neoplasm
Deepti Radia • 31 Mar 2025
1:05
Agents of interest in systemic mastocytosis and trials to keep an eye out for
Deepti Radia • 31 Mar 2025
View All Videos
4:47
Findings from the Phase II AMMO trial of ASTX727 in CMML and other MDS/MPN overlap syndromes
Daniel Wiseman • 6 Dec 2025
2:21
Multimodal assessment of CMML with extramedullary involvement reveals RAS pathway activation
Sanam Loghavi • 6 Dec 2025
1:18
Using molecular profiling and genomic insights to improve the management of CMML
Eric Padron • 22 Aug 2025
2:05
Targeting NET formation in patients with CMML: a novel therapeutic approach
Ami Patel • 22 Aug 2025
View All Videos

Conferences

ASH 2025
SOHO 2025
MPN Workshop of the Carolinas 2025
iwMPN 2025
EHA 2025
ASCO 2025
1:40
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
Ruben Mesa • 6 Dec 2025
1:26
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Ruben Mesa • 6 Dec 2025
3:32
The management of patients with ET or PV during pregnancy
Mary Frances McMullin • 7 Dec 2025
1:54
Therapeutic options available in the UK for patients with myelofibrosis
Mary Frances McMullin • 7 Dec 2025
View All Videos
1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
2:14
Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach
John Mascarenhas • 4 Sep 2025
10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
1:19
The value of fedratinib for the treatment of patients with MF in the second-line setting
Francesco Passamonti • 5 Sep 2025
View All Videos
2:47
The role of HMGA1 in driving MPN progression
Linda Resar • 11 Sep 2025
9:54
The potential of MDM2 inhibitors in MPNs: past and ongoing studies of navtemadlin
Pankit Vachhani • 12 Sep 2025
1:20
Could HMGA1 be used as a prognostic biomarker for MPN disease progression?
Linda Resar • 11 Sep 2025
3:37
The potential of HMGA1 as a novel therapeutic target in MPNs and other hematological malignancies
Linda Resar • 11 Sep 2025
View All Videos
1:27
Understanding drug-drug interactions in patients receiving both cardiac and oncology treatments
Alex Lyon • 28 Jun 2025
4:31
Cardiovascular health in patients with MPNs: risk stratification and management strategies
Alex Lyon • 28 Jun 2025
1:38
Prevention strategies for patients with MPNs at high risk of cardiovascular disease
Alex Lyon • 28 Jun 2025
10:43
Challenges of managing blast-phase MPNs: the role of transplant, impact of TP53 mutations & more
Adam Meadet al. • 28 Jun 2025
View All Videos
2:49
Real-world data on the treatment of adolescents and young adults with MPNs
Claire Harrison • 23 Jun 2025
2:45
An indirect comparison of the safety profiles of JAK inhibitors in patients with myelofibrosis
Lucia Masarova • 12 Jun 2025
4:28
Momelotinib in the treatment of myelofibrosis: pivotal Phase III trials
Prithviraj Bose • 12 Jun 2025
4:47
Impact of dual spleen response & transfusion independence in momelotinib-treated patients with MF
Francesca Palandri • 4 Jun 2025
View All Videos
1:52
Topline results from the SURPASS-ET trial: ropeginterferon alfa-2b versus anagrelide in ET
Lucia Masarova • 12 Jun 2025
2:17
A review of the clinical safety and efficacy of ruxolitinib 10 years after its approval for PV
Naveen Pemmaraju • 31 May 2025
0:57
Practice-changing findings in MPNs from ASCO 2025
Andrew Kuykendall • 1 Jun 2025
0:58
The IMproveMF study: combining imetelstat with ruxolitinib for the treatment of myelofibrosis
Andrew Kuykendall • 1 Jun 2025
View All Videos

lucia-masarova
Lucia Masarova
MD
The University of Texas MD Anderson Cancer Center
prithviraj-bose
Prithviraj Bose
MD
The University of Texas MD Anderson Cancer Center

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

Gold Supporter

Takeda

Bronze Supporter

Kartos Therapeutics, Inc.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

If you are interested in becoming a supporter of The Myeloproliferative Neoplasms Channel, please contact us.

The content of VJHemOnc is intended for healthcare professionals